The Health Ministry reports that yesterday afternoon, it received a report about a possible issue with one of the kits used for genetic screening through a nanochip, which is meant to detect changes in the BRCA 1 and 2 genes.
This report followed a case where a woman who initially received a negative test result was later diagnosed with breast cancer, and when she retested, she received a positive result. An inquiry at the health fund uncovered another similar case.
The nanochip test is designed to identify common genetic changes (frequent mutations) in the BRCA 1 and 2 genes among Jewish women. This specific test looks for 14 different mutations, which increase the risk of developing cancer. The screening is done using a blood sample and is generally recommended for women of Jewish descent, especially those who have not had cancer, although some cases may involve women who have. The test is advised for women aged 25 and older after a medical consultation.
Once the case was reported, the Health Ministry launched a thorough investigation and instructed laboratories and genetic centers to stop using this test. It’s important to note that, based on current information, this test was only used between August 2024 and January 2025. However, the ministry is evaluating the situation and may extend the testing period if necessary, depending on the findings.
Additionally, the ministry is looking into the event with the company involved and will determine which individuals who were tested may need to retest if needed.
The Health Ministry is continuing its investigation and will keep the public informed.